Aesica Appoints VP, Business Development and Business Development Director
News Oct 31, 2014
Aesica has announced the appointment of two senior business development positions. Detlef Behrens has been appointed to the role of Vice President, Business Development, Finished Dose with Sven Wrabletz joining as Business Development Director, Finished Dose.
Detlef has overall responsibility for business development and for finished dose services, covering formulation development, bulk manufacturing and packaging with a full international remit across the Group.
Sven is also responsible for finished dose development, manufacturing and packaging but with a geographic remit covering Northern Germany, Benelux and Eastern Europe. Both positions are based in Germany.
Detlef reports directly to Ian Muir, Managing Director, Finished Dose and prior to working for Aesica, Detlef held senior BD roles at Piramal and Next Pharma. As a qualified pharmacist he holds a PhD, and is a Board member and member of the Education Committee of DCAT.
Sven Wrabletz reports to Detlef Behrens, holds a Diplom-Betriebswirt (FH) and a Bachelor of Arts in International Business Administration and joined Aesica from Clondalkin, a packaging specialist.
Commenting on the new appointments, Ian Muir, Managing Director, Finished Dose remarked: “We are very pleased that Sven Wrabletz and Detlef Behrens have joined Aesica and look forward to the strong contribution that they are set to make to generate new business growth internationally, both in terms of sales and portfolio expansion.”
Concept Life Sciences appoints New Group Programme Manager and US Head of SalesNews
Key leadership appointments support integration of the Group and expansion in the US market.READ MORE
Alzheimer’s Drug Discovery Foundation Announces $1.8M in New FundingNews
The Alzheimer’s Drug Discovery Foundation (ADDF) announces nearly $1.8 million in new funding, which reflects a commitment to advancing drugs in or near human clinical trials. All five funded programs are potential treatments for Alzheimer’s disease and other forms of dementia.READ MORE
New Research Hub to Tackle Global Vaccination ChallengesNews
The University of Bristol will contribute to a new research hub to increase global immunisation coverage and improve response to viral outbreaks through the rapid and cost-effective deployment of vaccines.READ MORE